Antiviral Therapeutics Market - Global Forecast 2026-2032

The antiviral therapeutics market is experiencing rapid evolution as scientific innovation converges with new regulatory frameworks and shifting clinical priorities, creating meaningful opportunities and challenges for industry leaders. This report guides senior decision-makers through the trends and risks that matter most in today’s complex landscape.

Market Snapshot: Antiviral Therapeutics Market Growth

The Antiviral Therapeutics Market is projected to expand from USD 88.29 billion in 2025 to USD 95.06 billion in 2026, with an expected CAGR of 8.57% and anticipated value of USD 157.02 billion by 2032. Rising demand, ongoing scientific advancement, and regulatory momentum are driving robust sector growth and shifting competitive dynamics.

Scope & Segmentation

Disease Types: Targeted analysis covers COVID-19, cytomegalovirus, hepatitis C, herpes, HIV, influenza, and respiratory syncytial virus, each with unique clinical and adoption challenges.
Drug Classes: Assessed areas include fusion inhibitors, protease inhibitors, integrase inhibitors, monoclonal antibodies, interferons, polymerase inhibitors, and neuraminidase-targeting agents.
Therapy Types: Evaluation includes both prophylaxis and treatment-focused products, differentiating adoption drivers and operational needs.
Routes of Administration: Examination of oral, injectable, inhaled, and topical antivirals informs distribution and patient adherence strategies.
Distribution Channels: Market access and logistics are analyzed across hospital pharmacies, specialty clinics, retail, and online outlets.
Geographic Regions: In-depth insights provided for the Americas, Europe, Middle East & Africa, and Asia-Pacific, spotlighting regulatory and manufacturing differences affecting local strategies.
Key Technologies: Focus on precision biologics, monoclonal antibodies, small-molecule platforms, mRNA, and improved viral vector systems as engines of innovation.

Key Takeaways for Strategic Decision-Makers

Precision biologics and monoclonal antibody platforms have shifted the risk-benefit profile for targeted interventions, leading to increased efficacy and narrower indications.
Advances in mRNA, polymerase inhibitors, and supply chain resilience are compressing development timelines, supporting accelerated go-to-market strategies and platform validation.
Regulatory frameworks, particularly adaptive pathways and accelerated approvals, are fostering early lifecycle engagement and pragmatic trial designs for antiviral candidates.
Supply chain decisions increasingly emphasize nearshoring, dual-sourcing, and flexible manufacturing in response to operational risk and procurement volatility.
Regional differences in reimbursement models, regulatory maturity, and local investment in manufacturing influence both development priorities and commercial launch plans.
Collaborative partnerships, including contract manufacturing and joint innovation agreements, are critical for managing complexity and scaling production during demand surges.

Tariff Impact: How US Policy Is Reshaping Antiviral Supply Chains

Recent United States tariff measures and related trade policy shifts have raised costs for key ingredients and specialized antiviral components. Companies have responded by reevaluating contracts, moving toward nearshoring, and diversifying suppliers to maintain quality and cost control. Organizations are renegotiating procurement agreements and prioritizing regional manufacturing capacity, especially fill-and-finish capabilities, to shield operations from cost volatility. Health systems and payers have intensified scrutiny of pricing and accelerated adoption of value-based contracts to offset supply chain-driven cost pressures.

Methodology & Data Sources

This analysis uses a triangulated approach, combining structured interviews with clinicians, regulatory and supply chain experts, and commercial leaders, alongside in-depth review of published literature and real-world data. Analytical techniques include qualitative thematic review and comparative case study, with robust data validation ensuring reliable, actionable recommendations for stakeholders.

Why This Report Matters

Equips R&D, operations, and portfolio leaders with evidence-based guidance for navigating supply chain complexities and regulatory change in antiviral markets.
Supports effective scenario planning and resource allocation by illuminating region-specific risks and growth levers across all relevant antiviral segments.

Utilizing this report enables strategic alignment across scientific, operational, and commercial teams, fostering resilient product pipelines and successful market launches.

Conclusion

Aligning scientific advancement with operational reliability and adaptive regulatory strategy is essential for sustained commercial and clinical impact in antiviral therapeutics. This report delivers the actionable insight needed to inform strategic decisions and secure long-term value in an evolving global market.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Antiviral Therapeutics Market, by Disease Type

8.1. COVID-19
8.2. Cytomegalovirus
8.3. Hepatitis C
8.4. Herpes
8.5. Hiv
8.6. Influenza
8.7. Respiratory Syncytial Virus

9. Antiviral Therapeutics Market, by Drug Class

9.1. Fusion Inhibitors
9.2. Integrase Inhibitors
9.3. Interferons
9.4. Monoclonal Antibodies
9.5. Neuraminidase Inhibitors
9.6. Nnrtis
9.7. Nrtis
9.8. Polymerase Inhibitors
9.9. Protease Inhibitors

10. Antiviral Therapeutics Market, by Route Of Administration

10.1. Inhalation
10.2. Injectable
10.3. Oral
10.4. Topical

11. Antiviral Therapeutics Market, by Therapy Type

11.1. Prophylaxis
11.2. Treatment

12. Antiviral Therapeutics Market, by Distribution Channel

12.1. Hospital Pharmacy
12.2. Online Pharmacy
12.3. Retail Pharmacy
12.4. Specialty Clinics

13. Antiviral Therapeutics Market, by Region

13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific

14. Antiviral Therapeutics Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Antiviral Therapeutics Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. United States Antiviral Therapeutics Market
17. China Antiviral Therapeutics Market

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbott Laboratories
18.6. AbbVie Inc.
18.7. Alkem Laboratories Limited
18.8. AstraZeneca PLC
18.9. Atea Pharmaceuticals, Inc.
18.10. Aurobindo Pharma Limited
18.11. Bristol-Myers Squibb Company
18.12. Cipla Ltd.
18.13. Cocrystal Pharma, Inc.
18.14. Daiichi Sankyo Company, Ltd.
18.15. Dr. Reddy’s Laboratories Ltd.
18.16. Eli Lilly and Company
18.17. F. Hoffmann-La Roche Ltd.
18.18. Gilead Sciences, Inc.
18.19. GlaxoSmithKline plc
18.20. Hetero Labs Limited
18.21. Johnson & Johnson Services Inc.
18.22. Merck & Co., Inc.
18.23. Novartis AG
18.24. Pfizer Inc.
18.25. Sanofi S.A.
18.26. Sun Pharmaceutical Industries Limited
18.27. Syngene International Limited
18.28. Takeda Pharmaceutical Company Limited
18.29. Themis Medicare Ltd.
18.30. Venatorx Pharmaceuticals, Inc.
18.31. Viatris Inc.
18.32. Zydus Lifesciences Limited

List of Figures

FIGURE 1. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 110. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 112. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 113. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 114. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 115. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 124. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 125. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 127. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 135. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 137. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 138. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 139. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 140. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 141. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 143. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 144. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 145. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 146. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 155. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 156. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 157. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 158. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 159. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 161. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 162. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 164. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 165. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 167. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 168. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 169. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 170. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 171. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 173. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 174. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 175. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 176. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 177. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 178. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 179. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 180. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 181. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 182. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 183. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Antiviral Therapeutics market report include:

Abbott Laboratories
AbbVie Inc.
Alkem Laboratories Limited
AstraZeneca PLC
Atea Pharmaceuticals, Inc.
Aurobindo Pharma Limited
Bristol-Myers Squibb Company
Cipla Ltd.
Cocrystal Pharma, Inc.
Daiichi Sankyo Company, Ltd.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc
Hetero Labs Limited
Johnson & Johnson Services Inc.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Sun Pharmaceutical Industries Limited
Syngene International Limited
Takeda Pharmaceutical Company Limited
Themis Medicare Ltd.
Venatorx Pharmaceuticals, Inc.
Viatris Inc.
Zydus Lifesciences Limited

Table Information

Report Attribute	Details
No. of Pages	195
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 95.06 Billion
Forecasted Market Value ( USD ) by 2032	$ 157.02 Billion
Compound Annual Growth Rate	8.5%
Regions Covered	Global
No. of Companies Mentioned	29

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3504EUR$3,939USD£3,037GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3779EUR$4,249USD£3,276GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5123EUR$5,759USD£4,440GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6199EUR$6,969USD£5,372GBP

Market Snapshot: Antiviral Therapeutics Market Growth

Scope & Segmentation

Key Takeaways for Strategic Decision-Makers

Tariff Impact: How US Policy Is Reshaping Antiviral Supply Chains

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Antiviral Drugs Market - Global Forecast 2026-2032

Antivirals Market Report 2025

Antiviral Combination Therapy Market Report 2025

Antiviral Combination Therapy Market Outlook 2025-2034: Market Share, and Growth Analysis

Antiviral Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034